Your browser doesn't support javascript.
loading
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.
Fennell, Dean; Griffiths, Daniel; Eminton, Zina; Morgan-Fox, Abigail; Hill, Kayleigh; Ewings, Sean; Stuart, Charlotte; Johnson, Lucy; Mallard, Kim; Nye, Mavis; Darlison, Liz; Dulloo, Sean; Cave, Judith; Luo, Jin-Li; Taylor, Paul; Spicer, Jake; Poile, Charlotte; Bzura, Aleksandra; Griffiths, Gareth.
Afiliação
  • Fennell D; Mesothelioma Research Programme, Department of Genetics and Genome Biology, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Griffiths D; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK dpg1e20@soton.ac.uk.
  • Eminton Z; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Morgan-Fox A; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Hill K; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Ewings S; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Stuart C; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Johnson L; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Mallard K; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Nye M; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
  • Darlison L; Mesothelioma Research Programme, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Dulloo S; Department of Genetics and Genome Biology, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Cave J; Department of Oncology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Luo JL; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Taylor P; Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Spicer J; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Poile C; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Bzura A; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Griffiths G; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
BMJ Open ; 13(11): e073120, 2023 11 22.
Article em En | MEDLINE | ID: mdl-37993149
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mesotelioma Maligno / Mesotelioma Limite: Humans País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mesotelioma Maligno / Mesotelioma Limite: Humans País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido